Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer

Vincenzo Di Nunno, Alessia Cimadamore, Matteo Santoni, Marina Scarpelli, Michelangelo Fiorentino, Chiara Ciccarese, Roberto Iacovelli, Liang Cheng, Antonio Lopez-Beltran, Francesco Massari, Rodolfo Montironi

Research output: Contribution to journalComment/debate

2 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)2559-2564
Number of pages6
JournalFuture Oncology
Volume14
Issue number25
DOIs
StatePublished - Oct 1 2018

Fingerprint

Castration
Renal Cell Carcinoma
Prostatic Neoplasms
Bone and Bones
cabozantinib

Keywords

  • angiogenesis
  • bone metastasis
  • cabozantinib
  • castration-resistant prostate cancer
  • MET inhibitor
  • metastatic RCC
  • multityrosine kinases inhibitor
  • osteoblastic activation
  • renal cell carcinoma
  • target therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Di Nunno, V., Cimadamore, A., Santoni, M., Scarpelli, M., Fiorentino, M., Ciccarese, C., ... Montironi, R. (2018). Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. Future Oncology, 14(25), 2559-2564. https://doi.org/10.2217/fon-2018-0158

Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. / Di Nunno, Vincenzo; Cimadamore, Alessia; Santoni, Matteo; Scarpelli, Marina; Fiorentino, Michelangelo; Ciccarese, Chiara; Iacovelli, Roberto; Cheng, Liang; Lopez-Beltran, Antonio; Massari, Francesco; Montironi, Rodolfo.

In: Future Oncology, Vol. 14, No. 25, 01.10.2018, p. 2559-2564.

Research output: Contribution to journalComment/debate

Di Nunno, V, Cimadamore, A, Santoni, M, Scarpelli, M, Fiorentino, M, Ciccarese, C, Iacovelli, R, Cheng, L, Lopez-Beltran, A, Massari, F & Montironi, R 2018, 'Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer', Future Oncology, vol. 14, no. 25, pp. 2559-2564. https://doi.org/10.2217/fon-2018-0158
Di Nunno V, Cimadamore A, Santoni M, Scarpelli M, Fiorentino M, Ciccarese C et al. Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. Future Oncology. 2018 Oct 1;14(25):2559-2564. https://doi.org/10.2217/fon-2018-0158
Di Nunno, Vincenzo ; Cimadamore, Alessia ; Santoni, Matteo ; Scarpelli, Marina ; Fiorentino, Michelangelo ; Ciccarese, Chiara ; Iacovelli, Roberto ; Cheng, Liang ; Lopez-Beltran, Antonio ; Massari, Francesco ; Montironi, Rodolfo. / Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. In: Future Oncology. 2018 ; Vol. 14, No. 25. pp. 2559-2564.
@article{268ff1b37afa4c93a6f47921aca17790,
title = "Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer",
keywords = "angiogenesis, bone metastasis, cabozantinib, castration-resistant prostate cancer, MET inhibitor, metastatic RCC, multityrosine kinases inhibitor, osteoblastic activation, renal cell carcinoma, target therapy",
author = "{Di Nunno}, Vincenzo and Alessia Cimadamore and Matteo Santoni and Marina Scarpelli and Michelangelo Fiorentino and Chiara Ciccarese and Roberto Iacovelli and Liang Cheng and Antonio Lopez-Beltran and Francesco Massari and Rodolfo Montironi",
year = "2018",
month = "10",
day = "1",
doi = "10.2217/fon-2018-0158",
language = "English (US)",
volume = "14",
pages = "2559--2564",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "25",

}

TY - JOUR

T1 - Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer

AU - Di Nunno, Vincenzo

AU - Cimadamore, Alessia

AU - Santoni, Matteo

AU - Scarpelli, Marina

AU - Fiorentino, Michelangelo

AU - Ciccarese, Chiara

AU - Iacovelli, Roberto

AU - Cheng, Liang

AU - Lopez-Beltran, Antonio

AU - Massari, Francesco

AU - Montironi, Rodolfo

PY - 2018/10/1

Y1 - 2018/10/1

KW - angiogenesis

KW - bone metastasis

KW - cabozantinib

KW - castration-resistant prostate cancer

KW - MET inhibitor

KW - metastatic RCC

KW - multityrosine kinases inhibitor

KW - osteoblastic activation

KW - renal cell carcinoma

KW - target therapy

UR - http://www.scopus.com/inward/record.url?scp=85054894118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054894118&partnerID=8YFLogxK

U2 - 10.2217/fon-2018-0158

DO - 10.2217/fon-2018-0158

M3 - Comment/debate

VL - 14

SP - 2559

EP - 2564

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 25

ER -